Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 21 February 2012 | By Alexander Gaffney, RAC
A 2009 order by the Obama administration meant to ban registered lobbyists from serving on federal advisory committees-including those used by the US Food and Drug Administration (FDA) to provide it with expert opinions-has instead caused to those same lobbyists to cancel their lobbying registrations in order to continue to serve on the advisory committees, reports The Hill.
At least 22 current federal advisory committee members serving on Industry Trade Advisory Committees (ITACs) were found by The Hill to have cancelled their lobbying registrations after the Obama administration enacted the policy. Thirty-six other advisory committee members were registered to lobby at some point prior to serving on the advisory committees.
Any individual who spends more than 20% of his or her time conducting lobbying activities is required to register with the Senate under the terms of the Lobbying Disclosure Act, notes The Hill.
While The Hill only investigated the memberships of the 16 ITACs-groups convened by the International Trade Administration to give it advice-the behavior could extend to other federal advisory committees as well. There are approximately 1,000 advisory committees, including approximately 50 used by FDA.
The agency is not unfamiliar with conflicts of interest. A report by The Wall Street Journal on 11 January created an uproar after it revealed that a panel assessing birth control pills included members that had ties to Bayer, whose products were under review by the panel.
FDA responded to the controversy a week later. In a FDA Voice blog posting, Acting Associate Commissioner for Special Medical Programs Jill Hartzler said that FDA "did not identify any financial interests that would have precluded their participation," adding that regulations barred them from disclosing any information not requiring a conflict of interest waiver.
Requests for comment were not returned by FDA by the time of this article's publication.
Tags: Federal Advisory Committee, ITAC, Lobbyist, Lobby, Trade, Conflict of Interest, AdComm, Latest News, advisory committee
Regulatory Focus newsletters
All the biggest regulatory news and happenings.